Protas was formed amidst an international health crisis with the proof that a combination of expertly designed trials, careful use of routine health data and collaboration with frontline clinicians, can change the health of individuals as well as entire populations, and the health systems which support them. Protas represents a radical leap forward in the way that clinical trials can be conducted, and will combine deep expertise, scalable technology and a robust business model to enable earlier access to better treatments for common conditions.
We bring unparalleled knowledge and experience.
We are led by a highly respected Board and two of the most experienced and acclaimed clinical trialists in the world. Professor Sir Martin Landray, our CEO, has a long and distinguished career in delivering clinical trials, having worked on every aspect of their delivery. He was the co-principal investigator for the RECOVERY trial of treatments for COVID-19 and will use his experience to scale the delivery of trials.
Professor Sir Rory Collins, Vice-Chair of Protas, was instrumental in the ISIS trials of treatments for acute myocardial infarction and HPS trial of statins. Since 2001, he has been Principal Investigator of UK Biobank – a unique biomedical resource that involves half a million participants and enables scientific research into a broad range of diseases.
Adding to this strength in clinical trials, Protas is chaired by Lord Prior, Chair of NHS England, who will serve alongside Professor Sir John Bell, Professor Fiona Watt, Cathrin Petty and Sir Jonathan Symonds. More information about the whole team can be found on the ‘Our People’ page.
“A New National Purpose”: Protas named in report on innovation
Protas was this week named in a new report exploring how the UK should harness innovation in science and technology…
Protas signs strategic partnership with Moderna
Protas is delighted to announce a new strategic partnership with Moderna, the leading biotechnology company pioneering messenger RNA (mRNA). Moderna’s…